Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate. GC019F is in Phase I clinical trial for the. treatment of adult B cell acute lymphoblastic leukemia (B-ALL)
| Market Cap | 392.462 Million | Shares Outstanding | 72.678 Million | Avg 30-day Volume | 483.52 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.26 |
| Price to Revenue | 0.0 | Debt to Equity | 0.1202 | EBITDA | -79.331 Million |
| Price to Book Value | 3.9013 | Operating Margin | 0.0 | Enterprise Value | 590.753 Million |
| Current Ratio | 6.779 | EPS Growth | 0.812 | Quick Ratio | 6.609 |
| 1 Yr BETA | 1.8731 | 52-week High/Low | 6.99 / 1.4 | Profit Margin | 0.0 |
| Operating Cash Flow Growth | -46.4252 | Free Cash Flow to Firm (FCFF) TTM | -54.653 Million | Free Cash Flow to Equity (FCFE) TTM | -45.319 Million |
| Altman Z-Score | 9.7859 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 22:15:04 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 21:45:03 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 21:15:04 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 20:45:04 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 20:15:04 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 19:45:03 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 19:15:04 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 18:45:03 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 18:15:03 UTC | 3.6756 | 1.6444 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 17:45:04 UTC | 3.7391 | 1.5809 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 17:15:04 UTC | 3.7391 | 1.5809 | 4000000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 16:45:04 UTC | 3.7391 | 1.5809 | 4000000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 16:15:04 UTC | 3.7391 | 1.5809 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 15:45:03 UTC | 3.7428 | 1.5772 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 15:15:03 UTC | 3.7428 | 1.5772 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 14:45:04 UTC | 3.7411 | 1.5789 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 14:15:04 UTC | 3.7411 | 1.5789 | 3900000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 13:45:04 UTC | 3.7075 | 1.6125 | 3000000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 13:15:03 UTC | 3.7075 | 1.6125 | 3000000 |
| GRACELL BIOTECHNOLOGIES-ADR GRCL | 2023-11-28 12:45:04 UTC | 3.7075 | 1.6125 | 3000000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
